THE HUMAN FREQUENCY
Find Common Ground
Live Tune in →
HUMAN OS WIKI · 14 · UNDERSTANDING YOUR KIDS

MEDICATION DECISION OS

The 8 questions to ask the prescribing physician before any medication trial. The 30-day tracking sheet that turns prescriber appointments from guesswork into data. Sourced from Survival Blueprint Ch. 8.

8 min read Last updated October 2026 Source: Survival Blueprint, Ch. 8
A decision fork with two options, each fanning into a spread of possible outcomes A single starting point on the left splits into option A above and option B below. Each option fans out into five outcome dots on the right. Option A's outcomes are mostly gold, option B's are mostly magenta. The fork is labelled judge here, the process; the outcomes are labelled not here, the outcome. The fork Judge here Option A Option B Mostly good Mostly bad Luck
The mechanism at a glance. Judge the decision at the fork, by the process. The outcome at the end has luck in it.
Prescribers can decide better with a day-by-day record than with memories of how things went. — The Survival Blueprint, Chapter 8
SHORT ANSWER

This framework turns an ND medication decision from guesswork into a measurable trial using two artifacts: eight specific questions to ask the prescriber before starting, and a 30-day daily tracking sheet covering focus, mood, sleep, appetite, and side effects. The questions force the prescriber to name target symptoms, a timeline, and a stop condition; the daily data lets them see patterns that monthly recall misses. Pre-committing what not-working looks like keeps a medication from drifting on with no decision.

GET THE FREE PRINTABLE ↓ One page, wallet-card layout. Free. One email below, no spam, unsubscribe in a click.

The problem

Without a day-by-day record, a prescriber appointment runs on memories of how things went. The parent reports "I think it's working" or "I'm not sure," the prescriber decides from those impressions, and the next 30 days are an experiment with no data.

Nobody is at fault for this. The prescriber wasn't there for the 30 days. The child can't articulate side effects yet. The system asks for data and produces stories.

The Survival Blueprint Chapter 8 framework converts the medication decision into two artifacts: 8 specific questions to ask the prescriber before starting, and a 30-day tracking sheet that captures actual daily behavior. Together they turn medication into a measurable trial instead of a hopeful experiment.

The mechanism

Three things drive better medication decisions.

The 8 questions are forcing functions. Asking "what specific symptoms are we targeting" forces the prescriber to commit to measurable outcomes. Asking "what is the expected timeline for effects" forces a checkpoint. Asking "what is the plan if this doesn't work" gets a stop condition agreed before the trial starts, so the medication does not drift on with no one deciding.

Daily data outperforms monthly recall. The medication trial tracking sheet (Tool 4) captures focus, mood, sleep, appetite, and side effects daily for 30 days. The data gives the prescriber a day-by-day record to decide from, instead of the parent's memory of how things went.

Stop conditions are pre-committed. Questions 6 and 7 ask for the plan if the medication does not work and the point at which non-stimulant options come up, so what "not working" looks like is agreed before the trial starts: no noticeable improvement after the expected timeline, side effects your child cannot tolerate, personality flattening (the "zombie" risk), or insomnia. Pre-committed stop conditions prevent the slow drift into "the medication is not great, but I don't know how to bring it up."

THE TIMELINE TO EFFECT
Stimulants: usually the same day · Non-stimulants: usually weeks
Survival Blueprint Ch. 8, Section 8.2: ask how soon to expect effects before starting. Stimulants usually act the same day; non-stimulants such as atomoxetine and guanfacine usually take weeks to reach full effect. Knowing the timeline up front prevents premature "it's not working" conclusions.

The protocol

Five steps. The first is the 8-question script for the prescriber appointment; the rest cover what to do after.

STEP 01

Bring the 8 questions to the appointment

Print them. Read them off the page. Write down the answers. (1) What specific symptoms are we targeting? How will we measure whether it's working? (2) What's the expected timeline for effects? (3) What side effects should we watch for in the first two weeks? (4) How does this medication interact with puberty, growth, and appetite? (5) Should it be taken daily or only on school days? (6) What is the plan if this doesn't work? (7) At what point would we consider non-stimulant options? (8) How will we involve my child in the medication decision as they develop?

If a prescriber bristles at the questions, that's a flag about the prescriber, not the medication. Specialists who treat ND kids regularly are used to these questions and welcome them.
STEP 02

Set up the 30-day tracking sheet

Tool 4 from the Survival Blueprint is the canonical version. Daily metrics: focus, mood, sleep, appetite, side effects. Plus space for narrative observations (what the morning looked like, when the medication wore off, any specific incidents). Complete one row per day for 30 days. The sheet goes back to the prescriber at the next appointment.

If the tracking sheet feels like too much to maintain daily, simplify. Even a focus score and a mood score out of 10, with a one-line note on appetite, sleep and side effects, is more of a record than the prescriber would otherwise have.
STEP 03

Watch the first two weeks closely

Question 3 asks the prescriber which side effects to watch for in the first two weeks, so write the answer on the tracking sheet and check for those first. For stimulants, the American Academy of Pediatrics guideline lists the most common short-term side effects as appetite loss, stomach pain, headaches and sleep problems (Wolraich et al., 2019). The book adds one to watch for: a child who seems flat or "zombie-like" needs the medication adjusted. If anything in this period crosses an intolerable threshold, contact the prescriber. Don't wait for the scheduled follow-up.

Ask the prescriber how long a side effect is worth waiting out before you call, and write the answer on the sheet.
STEP 04

Bring the completed sheet to every follow-up

Prescribers can decide better with a day-by-day record than with memories of how things went. "Focus was 4 out of 10 the first week and 6 out of 10 the second, but appetite went from normal to reduced" is a conversation the prescriber can do something with. "I think it's helping but I'm not sure" is not.

If the prescriber doesn't ask for the sheet, hand it over anyway. Most clinicians appreciate it; some are stunned by it.
STEP 05

Apply the stop conditions if they hit

Re-evaluate the medication with the prescriber if (a) there is no noticeable improvement after the expected timeline, (b) side effects are intolerable, (c) your child seems flat or "zombie-like" (the book says the medication needs adjusting), or (d) a stimulant seems to be causing insomnia. The book's next steps run in this order: confirm the medication is being taken consistently → adjust the dose → try a different formulation → consider non-stimulant options → re-evaluate the diagnosis.

The last of the book's next steps, "re-evaluate the diagnosis," is for when several medication trials have failed. Ask whether the original diagnosis is right: anxiety, trauma, sleep disorders and thyroid conditions can look like ADHD and will not respond to ADHD medications.

The printable: the 8 questions

Print this. Bring it to the next prescriber appointment. The 30-day tracking sheet (Tool 4) is in the book.

8 QUESTIONS · BEFORE THE TRIAL
Survival Blueprint Ch. 8

01 · TARGET + MEASURE
What specific symptoms are we targeting? How will we know it's working?
Forces measurable outcomes.
02 · TIMELINE + SIDE EFFECTS
Expected timeline? Side effects to watch in the first 2 weeks?
Stimulants: usually the same day. Non-stimulants: usually weeks.
03 · GROWTH + APPETITE + DOSING
Effect on puberty/growth/appetite? Daily or school days only?
Appetite goes on the daily tracking sheet too.
04 · STOP CONDITIONS
What's the plan if this doesn't work? When would we consider non-stimulant?
Pre-commit before starting.
05 · CHILD'S VOICE
How will we involve my child in the decision as they develop?
Their say grows as they grow.

THE HUMAN FREQUENCY · FIND COMMON GROUND

Go deeper

This page is the surface. Each layer below goes further.

Share X Facebook LinkedIn Email WhatsApp

Common questions

What should you ask before starting your child on ADHD medication?
Eight questions, printed and read off the page: what specific symptoms are we targeting and how will we measure them; the expected timeline for effects; side effects to watch in the first two weeks; interactions with puberty, growth, and appetite; daily versus school-days-only dosing; the plan if it does not work; when to consider non-stimulants; and how to involve the child as they grow. A prescriber who bristles at these is itself a flag.
Why keep a medication tracking sheet?
Because daily data beats monthly recall. Tracking focus, mood, sleep, appetite, and side effects each day for 30 days gives the prescriber a day-by-day record to decide from, instead of memories of how things went.
How long does it take for ADHD medication to work?
It depends on the class. Stimulants usually act the same day, while non-stimulants such as atomoxetine and guanfacine usually take weeks to reach full effect. Ask the prescriber how soon to expect a change from the specific medication, before the first dose. Knowing this in advance prevents two common mistakes: concluding too early that a non-stimulant is not working, and expecting instant transformation from an extended-release formulation.
What side effects should you watch for?
The first two weeks are the window question 3 on the prescriber list names, so ask about the most common short-term side effects of stimulants, which the American Academy of Pediatrics guideline lists as appetite loss, stomach pain, headaches and sleep problems, and about your child seeming flat or zombie-like, which the book says means the medication needs adjusting. Ask how long each is worth waiting out before you call. Anything intolerable warrants calling the prescriber before the scheduled follow-up.
When should you stop or change a medication?
Agree the stop conditions with the prescriber before the first dose: no noticeable improvement after the expected timeline, side effects your child cannot tolerate, personality flattening (the zombie presentation, which means the medication needs adjusting), or insomnia that a stimulant seems to be causing. The Survival Blueprint's order for next steps is to confirm the medication is being taken consistently, adjust the dose, try a different formulation, consider non-stimulant options, and finally, if several trials have failed, re-evaluate the diagnosis, because anxiety, trauma, sleep disorders and thyroid conditions can look like ADHD and will not respond to ADHD medications.

Continue the wiki

More operating systems most readers of this page also need.

SOURCES & CITATIONS▾

All claims on this page are sourced from The Survival Blueprint, Chapter 8, except the list of common stimulant side effects in step 3, which comes from the American Academy of Pediatrics guideline the book points to. Primary sources cited:

  • Survival Blueprint Ch. 8: Section 8.2 (Questions to Ask the Prescribing Physician); Section 8.3 (Medication Trial Tracking Sheet, Tool 4).
  • Wolraich, M. L. et al. (2019). Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 144(4). The American Academy of Pediatrics guideline. DOI
  • Faraone, S. V. et al. (2021). The World Federation of ADHD International Consensus Statement: 208 Evidence-based Conclusions about the Disorder. DOI

Where we get our research: We cite peer-reviewed work by its DOI, so each reference above opens the article itself. Where a framework's owner published a book rather than a paper, we name the author, year and publisher and link the publisher's page. The most common are the Gottman Institute's research, Stephen Porges's The Polyvagal Theory (Norton, 2011) and his 2023 reply to its critics, and Fisher and Ury's Getting to Yes (Penguin). Where we have no peer-reviewed article, we name the framework's author and say so. See our editorial policy for the full sourcing standard.